Spots Global Cancer Trial Database for Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
Official Title: Evaluating the Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
Study ID: NCT05045963
Interventions
Study Description
Brief Summary: This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the progression of sepsis is not known.
Detailed Description: PRIMARY OBJECTIVE: I. To assess the impact of beta-lactam (BL) + aminoglycoside (AG) combination therapy in hypotensive septic oncology patients. OUTLINE: Patients' medical charts are reviewed retrospectively.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Jeffrey J Bruno
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
